Loading...
•
May 31
AngioDynamics Q4 2025 Earnings Report
AngioDynamics reported Q4 2025 results with strong Med Tech growth and positive adjusted EBITDA despite a net loss.
Key Takeaways
The company achieved 12.7% revenue growth in Q4 2025, driven by 22% Med Tech sales increase. It recorded a GAAP net loss but improved adjusted EBITDA, supported by operational efficiency and strong cash flow.
Revenue grew 12.7% year over year to $80.2M
Med Tech sales surged 22% driven by Auryon and thrombectomy platforms
Positive adjusted EBITDA of $3.4M achieved in the quarter
Generated $16.2M in free cash flow due to operational efficiency
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The company expects continued revenue growth and positive free cash flow in FY2026, with some tariff-related headwinds.
Positive Outlook
- FY2026 revenue expected at $305M to $310M
- Med Tech sales growth projected at 12% to 15%
- Positive free cash flow anticipated for full year
- Gross margin expected between 53.5% and 55.5%
- Enhanced financial flexibility from $25M revolving credit facility
Challenges Ahead
- Tariff impact expected to reduce gross margin by 56 basis points
- Pro forma adjusted EBITDA guidance as low as $3M
- Adjusted EPS expected to remain negative at ($0.35) to ($0.25)
- Potential $4M to $6M impact from tariffs in FY2026
- Gross margin guidance lower due to tariff headwinds
Revenue & Expenses
Visualization of income flow from segment revenue to net income